Originally published as JCO Early Release 10.1200/JCO.2007.15.2546 on April 21 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by San-Miguel, J. Articles by Anderson, K. C. PubMed PubMed Citation Articles by San-Miguel, J. Articles by Anderson, K. C.

Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents

Jesús San-Miguel, Jean-Luc Harousseau, Douglas Joshua, Kenneth C. Anderson

From the Servicio de Hematología, Hospital Universitario de Salamanca (Centro de Investigación del Cáncer–Instituto de Biología Molecular del Centro del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas) Salamanca, Spain; University Hospital Nantes, Nantes, France; Institute of Hematology, Royal Prince Alfred Hospital, Sidney, Australia; and the Dana-Farber Cancer Institute, Boston, MA

Corresponding author: Jesús San-Miguel, MD, PhD, Servicio de Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, 37007 Salamanca, Spain; e-mail: sanmigiz{at}usal.es

Progress in the understanding of multiple myeloma (MM) cell biology has led to the identification of new relevant prognostic factors and subsequently different risk groups. This concept, together with the recent discovery of new drugs with novel mechanisms of action, will probably lead to individualized treatment according to the different patients’ characteristics. In this review, we focus on current available agents already approved for MM, and discuss individualized treatment approaches for both transplantation candidates (subdivided into standard and high-risk patients) and elderly patients. Future progress in MM will be based on using science to inform the design of the optimal combined treatments, and high throughput assays that can assess the ability of combination therapies to induce death of MM cells, both alone and in the bone marrow microenvironment.

published online ahead of print at www.jco.org on April 21, 2008.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				B. G.M. Durie Treatment of Myeloma -- Are We Making Progress? N. Engl. J. Med., August 28, 2008; 359(9): 964 - 966. [Full Text] [PDF]